Efficacy of liraglutide in combination therapy of patients with psoriasis combined with metabolic disorders: a meta-analysis of observational and controlled studies

BACKGROUND : Psoriasis is characterized by a high frequency of comorbid metabolic disorders, including obesity and type 2 diabetes mellitus. There are limited data on the efficacy of glucagon-like peptide-1 receptor agonist for the treatment of metabolic disorders in patients with psoriasis. AIM: Analysis of the effectiveness of liraglutide in the complex therapy of patients with psoriasis in combination with metabolic disorders. MATERIALS AND METHODS : The PubMed database was searched for studies using the keywords "psoriasis" and "liraglutide". 23 publications were found, the final analysis included 5 studies with a total sample size of 52 patients with psoriasis combined with metabolic disorders (type 2 diabetes mellitus and obesity). The effect of liraglutide on the prevalence and severity of psoriasis was assessed by the dynamics of the lesion area and psoriasis severity index (PASI), quality of life according to the DLQI questionnaire and the level of fasting plasma glucose, glycated hemoglobin, and body mass index. The results are presented as the weighted mean difference (WMD) and 95% confidence interval (CI). RESULTS : The duration of liraglutide therapy ranged from 8 to 16 weeks. The liraglutide dose was titrated from 0.6 mg/day to 3.0 mg/day. Significant dynamics of the WMD indices PASI (-6.95 [95% CI -11.59; -2.32]) and DLQI (-6.95 [95% CI -11.59; -2.32]), as well as the body mass index (-2.97 [95% CI -3.58; -2.37]) were demonstrated during liraglutide therapy. No significant difference in glucose and glycated hemoglobin levels was found. CONCLUSION : The results of the meta-analysis demonstrate that the use of liraglutide in combination therapy for psoriasis helps to reduce BMI, the prevalence and severity of psoriasis, and improve the quality of life of patients.